KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Common Equity: 2018-2025

Historic Common Equity for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $365.8 million.

  • Aurinia Pharmaceuticals' Common Equity fell 5.73% to $365.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $365.8 million, marking a year-over-year decrease of 5.73%. This contributed to the annual value of $377.5 million for FY2024, which is 0.13% down from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Common Equity is $365.8 million, which was up 9.09% from $335.3 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Common Equity registered a high of $479.1 million during Q4 2021, and its lowest value of $298.2 million during Q3 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Common Equity value was $377.5 million (recorded in 2024), while the average stood at $372.1 million.
  • Data for Aurinia Pharmaceuticals' Common Equity shows a peak YoY increase of 42.01% (in 2022) and a maximum YoY decrease of 15.37% (in 2022) over the last 5 years.
  • Over the past 5 years, Aurinia Pharmaceuticals' Common Equity (Quarterly) stood at $479.1 million in 2021, then fell by 15.37% to $405.4 million in 2022, then decreased by 6.78% to $378.0 million in 2023, then declined by 0.13% to $377.5 million in 2024, then declined by 5.73% to $365.8 million in 2025.
  • Its Common Equity was $365.8 million in Q3 2025, compared to $335.3 million in Q2 2025 and $350.2 million in Q1 2025.